Literature DB >> 19505479

Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.

Edwin H Rydberg1, Antonella Cellucci, Linda Bartholomew, Marco Mattu, Gaetano Barbato, Steven W Ludmerer, Donald J Graham, Sergio Altamura, Giacomo Paonessa, Raffaele De Francesco, Giovanni Migliaccio, Andrea Carfí.   

Abstract

Hepatitis C virus (HCV) exists in six major genotypes. Compared with the 1b enzyme, genotype 2b HCV polymerase exhibits a more than 100-fold reduction in sensitivity to the indole-N-acetamide class of non-nucleoside inhibitors. These compounds have been shown to bind in a pocket occupied by helix A of the mobile Lambda1 loop in the apoenzyme. The three-dimensional structure of the HCV polymerase from genotype 2b was determined to 1.9-A resolution and compared with the genotype 1b enzyme. This structural analysis suggests that genotypic variants result in a different shape of the inhibitor binding site. Mutants of the inhibitor binding pocket were generated in a 1b enzyme and evaluated for their binding affinity and sensitivity to inhibition by indole-N-acetamides. Most of the point mutants showed little variation in activity and IC(50), with the exception of 15- and 7-fold increases in IC(50) for Leu392Ile and Val494Ala mutants (1b-->2b), respectively. Furthermore, a 1b replicon with 20-fold resistance to this class of inhibitors was selected and shown to contain the Leu392Ile mutation. Chimeric enzymes, where the 2b fingertip Lambda1 loop, pocket or both replaced the corresponding regions of the 1b enzyme, were also generated. The fingertip chimera retained 1b-like inhibitor binding affinity, whereas the other two chimeric constructs and the 2b enzyme displayed between 50- and 100-fold reduction in binding affinity. Together, these data suggest that differences in the amino acid composition and shape of the indole-N-acetamide binding pocket are responsible for the resistance of the 2b polymerase to this class of inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505479     DOI: 10.1016/j.jmb.2009.06.012

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

1.  Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Authors:  Mengping Liu; Maria Tuttle; Min Gao; Julie A Lemm
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

2.  Impact of mutations on the allosteric conformational equilibrium.

Authors:  Patrick Weinkam; Yao Chi Chen; Jaume Pons; Andrej Sali
Journal:  J Mol Biol       Date:  2012-12-07       Impact factor: 5.469

3.  TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.

Authors:  Benoit Devogelaere; Jan Martin Berke; Leen Vijgen; Pascale Dehertogh; Els Fransen; Erna Cleiren; Liesbet van der Helm; Origène Nyanguile; Abdellah Tahri; Katie Amssoms; Oliver Lenz; Maxwell D Cummings; Reginald F Clayton; Sandrine Vendeville; Pierre Raboisson; Kenneth A Simmen; Gregory C Fanning; Tse-I Lin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-18       Impact factor: 5.191

4.  Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.

Authors:  Lenore A Pelosi; Stacey Voss; Mengping Liu; Min Gao; Julie A Lemm
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

5.  Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.

Authors:  Brittny C Davis; Ian F Thorpe
Journal:  Proteins       Date:  2012-09-15

6.  1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Authors:  Origène Nyanguile; Benoit Devogelaere; Leen Vijgen; Walter Van den Broeck; Frederik Pauwels; Maxwell D Cummings; Hendrik L De Bondt; Ann M Vos; Jan M Berke; Oliver Lenz; Geneviève Vandercruyssen; Katrien Vermeiren; Wendy Mostmans; Pascale Dehertogh; Frédéric Delouvroy; Sandrine Vendeville; Koen VanDyck; Koen Dockx; Erna Cleiren; Pierre Raboisson; Kenneth A Simmen; Gregory C Fanning
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

7.  Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.

Authors:  Auda A Eltahla; Enoch Tay; Mark W Douglas; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.938

8.  Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.

Authors:  Julie A Lemm; Mengping Liu; Robert G Gentles; Min Ding; Stacey Voss; Lenore A Pelosi; Ying-Kai Wang; Karen L Rigat; Kathleen W Mosure; John A Bender; Jay O Knipe; Richard Colonno; Nicholas A Meanwell; John F Kadow; Kenneth S Santone; Susan B Roberts; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.